Vivodyne
We accelerate the discovery of cures to human diseases with ultra-scalable drug testing on lab-grown human tissues.
We accelerate the discovery of cures to human diseases with ultra-scalable drug testing on lab-grown human tissues.
Vivodyne is a biotechnology startup founded in 2020 in the United States that aims to revolutionize the drug testing process. With the slogan "We accelerate the discovery of cures to human diseases with ultra-scalable drug testing on lab-grown human tissues," Vivodyne is focused on facilitating the discovery of cures for human diseases through highly scalable drug testing on lab-grown 3D human tissues. The company recently received a notable $38.00M Seed Round investment on 22 November 2023. The investment was led by Khosla Ventures, Kairos Ventures, Bison Ventures, MBX Capital, and CS Venture Opportunities Fund. Vivodyne's innovative approach to drug testing has garnered significant interest and support from prominent venture capital firms, positioning the company for potential growth and impact in the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $38.00M | 5 |
|
22 Nov 2023 |
| Seed Round | $2.00M | 1 |
|
11 Mar 2021 |
No recent news or press coverage available for Vivodyne.
We care about your data, and we'd love to use cookies make your experience better.
